Immuron Ltd
IMRNNasdaq
$1.21
↑ +7.1%Jul 17 close · end-of-day
Price
1Y↓ -35.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.
- CEO
- Steven Lydeamore
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Website
- immuron.com.au
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 20, 2026
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.